These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25013030)

  • 1. The role of worksite health screening: a policy statement from the American Heart Association.
    Arena R; Arnett DK; Terry PE; Li S; Isaac F; Mosca L; Braun L; Roach WH; Pate RR; Sanchez E; Carnethon M; Whitsel LP
    Circulation; 2014 Aug; 130(8):719-34. PubMed ID: 25013030
    [No Abstract]   [Full Text] [Related]  

  • 2. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Levine BD; Washington RL; Baggish AL; Kovacs RJ; Maron MS;
    Circulation; 2015 Dec; 132(22):e267-72. PubMed ID: 26527714
    [No Abstract]   [Full Text] [Related]  

  • 3. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Levine BD; Washington RL; Baggish AL; Kovacs RJ; Maron MS
    J Am Coll Cardiol; 2015 Dec; 66(21):2356-2361. PubMed ID: 26542659
    [No Abstract]   [Full Text] [Related]  

  • 4. ACC/AHA/SCAI 2014 health policy statement on structured reporting for the cardiac catheterization laboratory: a report of the American College of Cardiology Clinical Quality Committee.
    Sanborn TA; Tcheng JE; Anderson HV; Chambers CE; Cheatham SL; DeCaro MV; Durack JC; Everett AD; Gordon JB; Hammond WE; Hijazi ZM; Kashyap VS; Knudtson M; Landzberg MJ; Martinez-Rios MA; Riggs LA; Sim KH; Slotwiner DJ; Solomon H; Szeto WY; Weiner BH; Weintraub WS; Windle JR
    Circulation; 2014 Jun; 129(24):2578-609. PubMed ID: 24682349
    [No Abstract]   [Full Text] [Related]  

  • 5. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
    Yancy CW; Jessup M; Bozkurt B; Butler J; Casey DE; Drazner MH; Fonarow GC; Geraci SA; Horwich T; Januzzi JL; Johnson MR; Kasper EK; Levy WC; Masoudi FA; McBride PE; McMurray JJ; Mitchell JE; Peterson PN; Riegel B; Sam F; Stevenson LW; Tang WH; Tsai EJ; Wilkoff BL
    Circulation; 2013 Oct; 128(16):1810-52. PubMed ID: 23741057
    [No Abstract]   [Full Text] [Related]  

  • 6. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Bonow RO; Nishimura RA; Thompson PD; Udelson JE;
    Circulation; 2015 Dec; 132(22):e292-7. PubMed ID: 26621646
    [No Abstract]   [Full Text] [Related]  

  • 7. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 4: Congenital Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Van Hare GF; Ackerman MJ; Evangelista JA; Kovacs RJ; Myerburg RJ; Shafer KM; Warnes CA; Washington RL;
    Circulation; 2015 Dec; 132(22):e281-91. PubMed ID: 26621645
    [No Abstract]   [Full Text] [Related]  

  • 8. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services.
    Arnett DK; Goodman RA; Halperin JL; Anderson JL; Parekh AK; Zoghbi WA
    J Am Coll Cardiol; 2014 Oct; 64(17):1851-6. PubMed ID: 25219921
    [No Abstract]   [Full Text] [Related]  

  • 9. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Zipes DP; Kovacs RJ;
    Circulation; 2015 Dec; 132(22):e256-61. PubMed ID: 26621642
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.
    ; ; ; ; Wann LS; Curtis AB; Ellenbogen KA; Estes NA; Ezekowitz MD; Jackman WM; January CT; Lowe JE; Page RL; Slotwiner DJ; Stevenson WG; Tracy CM; Fuster V; Rydén LE; Cannom DS; Crijns HJ; Curtis AB; Ellenbogen KA; Halperin JL; Le Heuzey J; Kay GN; Lowe JE; Olsson SB; Prystowsky EN; Tamargo JL; Wann LS
    Circulation; 2013 May; 127(18):1916-26. PubMed ID: 23545139
    [No Abstract]   [Full Text] [Related]  

  • 11. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Jacobs AK; Anderson JL; Halperin JL
    J Am Coll Cardiol; 2014 Sep; 64(13):1373-84. PubMed ID: 25103073
    [No Abstract]   [Full Text] [Related]  

  • 12. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, and Impact: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Levine BD; Baggish AL; Kovacs RJ; Link MS; Maron MS; Mitchell JH;
    Circulation; 2015 Dec; 132(22):e262-6. PubMed ID: 26621643
    [No Abstract]   [Full Text] [Related]  

  • 13. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension: A Scientific Statement from the American Heart Association and the American College of Cardiology.
    Black HR; Sica D; Ferdinand K; White WB;
    Circulation; 2015 Dec; 132(22):e298-302. PubMed ID: 26621647
    [No Abstract]   [Full Text] [Related]  

  • 14. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: Sickle Cell Trait: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Harris KM; Thompson PD; Eichner ER; Steinberg MH;
    Circulation; 2015 Dec; 132(22):e343-5. PubMed ID: 26527715
    [No Abstract]   [Full Text] [Related]  

  • 15. Worksite wellness programs for cardiovascular disease prevention: a policy statement from the American Heart Association.
    Carnethon M; Whitsel LP; Franklin BA; Kris-Etherton P; Milani R; Pratt CA; Wagner GR; ; ; ;
    Circulation; 2009 Oct; 120(17):1725-41. PubMed ID: 19794121
    [No Abstract]   [Full Text] [Related]  

  • 16. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 11: Drugs and Performance-Enhancing Substances: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Estes NA; Kovacs RJ; Baggish AL; Myerburg RJ;
    Circulation; 2015 Dec; 132(22):e330-3. PubMed ID: 26621651
    [No Abstract]   [Full Text] [Related]  

  • 17. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 13: Commotio Cordis: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Link MS; Estes NA; Maron BJ;
    Circulation; 2015 Dec; 132(22):e339-42. PubMed ID: 26621653
    [No Abstract]   [Full Text] [Related]  

  • 18. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.
    Anderson JL; Heidenreich PA; Barnett PG; Creager MA; Fonarow GC; Gibbons RJ; Halperin JL; Hlatky MA; Jacobs AK; Mark DB; Masoudi FA; Peterson ED; Shaw LJ
    J Am Coll Cardiol; 2014 Jun; 63(21):2304-22. PubMed ID: 24681044
    [No Abstract]   [Full Text] [Related]  

  • 19. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
    Jacobs AK; Kushner FG; Ettinger SM; Guyton RA; Anderson JL; Ohman EM; Albert NM; Antman EM; Arnett DK; Bertolet M; Bhatt DL; Brindis RG; Creager MA; DeMets DL; Dickersin K; Fonarow GC; Gibbons RJ; Halperin JL; Hochman JS; Koster MA; Normand SL; Ortiz E; Peterson ED; Roach WH; Sacco RL; Smith SC; Stevenson WG; Tomaselli GF; Yancy CW; Zoghbi WA
    Circulation; 2013 Jan; 127(2):268-310. PubMed ID: 23230312
    [No Abstract]   [Full Text] [Related]  

  • 20. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Mitten MJ; Zipes DP; Maron BJ; Bryant WJ;
    Circulation; 2015 Dec; 132(22):e346-9. PubMed ID: 26621654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.